IMM Stock Overview
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Immutep Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.36 |
| 52 Week High | AU$0.42 |
| 52 Week Low | AU$0.23 |
| Beta | 1.83 |
| 1 Month Change | -1.37% |
| 3 Month Change | -2.70% |
| 1 Year Change | 44.00% |
| 3 Year Change | -16.28% |
| 5 Year Change | 28.57% |
| Change since IPO | -88.00% |
Recent News & Updates
Shareholder Returns
| IMM | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -11.1% | -1.1% | -0.6% |
| 1Y | 44.0% | -7.0% | 5.7% |
Return vs Industry: IMM exceeded the Australian Biotechs industry which returned -7% over the past year.
Return vs Market: IMM exceeded the Australian Market which returned 5.7% over the past year.
Price Volatility
| IMM volatility | |
|---|---|
| IMM Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.4% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: IMM has not had significant price volatility in the past 3 months.
Volatility Over Time: IMM's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Marc Voigt | www.immutep.com |
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease.
Immutep Limited Fundamentals Summary
| IMM fundamental statistics | |
|---|---|
| Market cap | AU$427.98m |
| Earnings (TTM) | -AU$40.50m |
| Revenue (TTM) | AU$3.93m |
108.9x
P/S Ratio-10.6x
P/E RatioIs IMM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMM income statement (TTM) | |
|---|---|
| Revenue | AU$3.93m |
| Cost of Revenue | AU$37.72m |
| Gross Profit | -AU$33.79m |
| Other Expenses | AU$6.71m |
| Earnings | -AU$40.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.034 |
| Gross Margin | -859.57% |
| Net Profit Margin | -1,030.32% |
| Debt/Equity Ratio | 0.8% |
How did IMM perform over the long term?
See historical performance and comparison